MedTrace Logo

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

NCT06585449 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.

Conditions

Interventions

DRUG

ALN-HTT02

ALN-HTT02 will be administered intrathecally

DRUG

Placebo

Placebo will be administered intrathecally

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Alnylam Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2028-07-05
Completion
2028-07-05
FDA Drug
Yes

Countries

  • Canada
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06585449 on ClinicalTrials.gov